Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 475 entries
Sorted by: Best Match Show Resources per page
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.

ClinicoEconomics and outcomes research : CEOR

Casado LF, Burgos A, González-Haba E, Loscertales J, Krivasi T, Orofino J, Rubio-Terres C, Rubio-Rodríguez D.
PMID: 27703384
Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016.

OBJECTIVE: To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make them unsuitable for full-dose fludarabine-based...

Cite
Casado LF, Burgos A, González-Haba E, et al. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016;8:475-484doi: 10.2147/CEOR.S114524.
Casado, L. F., Burgos, A., González-Haba, E., Loscertales, J., Krivasi, T., Orofino, J., Rubio-Terres, C., & Rubio-Rodríguez, D. (2016). Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. ClinicoEconomics and outcomes research : CEOR, 8475-484. https://doi.org/10.2147/CEOR.S114524
Casado, Luis Felipe, et al. "Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain." ClinicoEconomics and outcomes research : CEOR vol. 8 (2016): 475-484. doi: https://doi.org/10.2147/CEOR.S114524
Casado LF, Burgos A, González-Haba E, Loscertales J, Krivasi T, Orofino J, Rubio-Terres C, Rubio-Rodríguez D. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016. PMID: 27703384; PMCID: PMC5036824.
Copy Download .nbib Format: NLM
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.

OncoTargets and therapy

Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S.
PMID: 28223822
Onco Targets Ther. 2017 Feb 07;10:645-656. doi: 10.2147/OTT.S102646. eCollection 2017.

Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel...

Cite
Huber H, Edenhofer S, Estenfelder S, et al. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. Onco Targets Ther. 2017;10:645-656doi: 10.2147/OTT.S102646.
Huber, H., Edenhofer, S., Estenfelder, S., & Stilgenbauer, S. (2017). Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. OncoTargets and therapy, 10645-656. https://doi.org/10.2147/OTT.S102646
Huber, Henriette, et al. "Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia." OncoTargets and therapy vol. 10 (2017): 645-656. doi: https://doi.org/10.2147/OTT.S102646
Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. Onco Targets Ther. 2017 Feb 07;10:645-656. doi: 10.2147/OTT.S102646. eCollection 2017. PMID: 28223822; PMCID: PMC5308588.
Copy Download .nbib Format: NLM
Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia.

Experimental hematology & oncology

Garrote H, de la Fuente A, Oña R, Rodríguez I, Echevarría JE, Sepúlveda JM, García JF.
PMID: 25767742
Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015.

A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and rituximab, which produced a complete remission. Eight months after the last dose of rituximab he had visual disturbance, diminished muscular strength in the right arm...

Cite
Garrote H, de la Fuente A, Oña R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015;4:8doi: 10.1186/s40164-015-0003-4.
Garrote, H., de la Fuente, A., Oña, R., Rodríguez, I., Echevarría, J. E., Sepúlveda, J. M., & García, J. F. (2015). Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Experimental hematology & oncology, 48. https://doi.org/10.1186/s40164-015-0003-4
Garrote, Heidys, et al. "Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia." Experimental hematology & oncology vol. 4 (2015): 8. doi: https://doi.org/10.1186/s40164-015-0003-4
Garrote H, de la Fuente A, Oña R, Rodríguez I, Echevarría JE, Sepúlveda JM, García JF. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015. PMID: 25767742; PMCID: PMC4357158.
Copy Download .nbib Format: NLM
Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.

International journal of clinical and experimental medicine

Lei XR, Chen HL, Wang FX, Bai J, He AL.
PMID: 26550118
Int J Clin Exp Med. 2015 Aug 15;8(8):12064-75. eCollection 2015.

OBJECTIVES: The aim of the article is to critically appraise and synthesize available evidence regarding the efficacy and regimen-related toxicity (RRT) of Busulfan plus fludarabine (BuFlu) compared to busulfan plus cyclophosphamide (BuCy) as a conditioning regimen, prior to allogeneic...

Cite
Lei XR, Chen HL, Wang FX, et al. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis. Int J Clin Exp Med. 2015;8(8):12064-75
Lei, X. R., Chen, H. L., Wang, F. X., Bai, J., & He, A. L. (2015). Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis. International journal of clinical and experimental medicine, 8(8), 12064-75.
Lei, Xiao-Ru, et al. "Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis." International journal of clinical and experimental medicine vol. 8,8 (2015): 12064-75.
Lei XR, Chen HL, Wang FX, Bai J, He AL. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis. Int J Clin Exp Med. 2015 Aug 15;8(8):12064-75. eCollection 2015. PMID: 26550118; PMCID: PMC4612803.
Copy Download .nbib Format: NLM
Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.

Archives of medical science : AMS

Šimkovič M, Motyčková M, Belada D, Vodárek P, Kapoor R, Jaffar H, Vrbacký F, Žák P, Smolej L.
PMID: 27186190
Arch Med Sci. 2016 Apr 01;12(2):421-7. doi: 10.5114/aoms.2016.55425. Epub 2015 Dec 08.

INTRODUCTION: High-dose methylprednisolone (HDMP) in combination with rituximab is active in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL), but serious infections are frequent. Recently published data suggested that high-dose dexamethasone might be equally effective as HDMP despite a...

Cite
Šimkovič M, Motyčková M, Belada D, et al. Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. Arch Med Sci. 2015;12(2):421-7doi: 10.5114/aoms.2016.55425.
Šimkovič, M., Motyčková, M., Belada, D., Vodárek, P., Kapoor, R., Jaffar, H., Vrbacký, F., Žák, P., & Smolej, L. (2016). Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. Archives of medical science : AMS, 12(2), 421-7. https://doi.org/10.5114/aoms.2016.55425
Šimkovič, Martin, et al. "Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia." Archives of medical science : AMS vol. 12,2 (2016): 421-7. doi: https://doi.org/10.5114/aoms.2016.55425
Šimkovič M, Motyčková M, Belada D, Vodárek P, Kapoor R, Jaffar H, Vrbacký F, Žák P, Smolej L. Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. Arch Med Sci. 2016 Apr 01;12(2):421-7. doi: 10.5114/aoms.2016.55425. Epub 2015 Dec 08. PMID: 27186190; PMCID: PMC4848354.
Copy Download .nbib Format: NLM
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Seminars in oncology

Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH.
PMID: 28140090
Semin Oncol. 2002 Feb;29(1):36-40. doi: 10.1053/sonc.2002.30152.

Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe. The reasons...

Cite
Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;29(1):36-40doi: 10.1053/sonc.2002.30152.
Czuczman, M. S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z. P., McCarthy, P., Skipper, M., Brown, K., Miller, K., Wentling, D., Klippenstein, D., Loud, P., Rock, M. K., Benyunes, M., Grillo-López, A. J., & Bernstein, S. H. (2002). Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in oncology, 29(1), 36-40. https://doi.org/10.1053/sonc.2002.30152
Czuczman, Myron S, et al. "Rituximab in combination with CHOP or fludarabine in low-grade lymphoma." Seminars in oncology vol. 29,1 (2002): 36-40. doi: https://doi.org/10.1053/sonc.2002.30152
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002 Feb;29(1):36-40. doi: 10.1053/sonc.2002.30152. PMID: 28140090.
Copy Download .nbib Format: NLM
Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI).

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Raut SS, Shah SA, Patel KA, Shah KM, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Parekh BB, Shukla SN.
PMID: 25548437
Indian J Hematol Blood Transfus. 2015 Mar;31(1):1-8. doi: 10.1007/s12288-014-0397-x. Epub 2014 May 08.

Fifteen patients, with a median age of 19 years having severe aplastic anaemia (SAA) underwent human leucocyte antigen (HLA) identical sibling donor hematopoietic stem cell transplantation (HSCT) using conditioning regimens containing cyclophosphamide with antithymocyte globulin (ATG) or a combination...

Cite
Raut SS, Shah SA, Patel KA, et al. Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI). Indian J Hematol Blood Transfus. 2014;31(1):1-8doi: 10.1007/s12288-014-0397-x.
Raut, S. S., Shah, S. A., Patel, K. A., Shah, K. M., Anand, A. S., Talati, S. S., Panchal, H. P., Patel, A. A., Parikh, S. K., Parekh, B. B., & Shukla, S. N. (2015). Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI). Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 31(1), 1-8. https://doi.org/10.1007/s12288-014-0397-x
Raut, Shreeniwas S, et al. "Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI)." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 31,1 (2015): 1-8. doi: https://doi.org/10.1007/s12288-014-0397-x
Raut SS, Shah SA, Patel KA, Shah KM, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Parekh BB, Shukla SN. Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI). Indian J Hematol Blood Transfus. 2015 Mar;31(1):1-8. doi: 10.1007/s12288-014-0397-x. Epub 2014 May 08. PMID: 25548437; PMCID: PMC4275516.
Copy Download .nbib Format: NLM
Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma.

Therapeutic advances in psychopharmacology

Usta NG, Poyraz CA, Aktan M, Duran A.
PMID: 25489479
Ther Adv Psychopharmacol. 2014 Dec;4(6):276-81. doi: 10.1177/2045125314553610.

BACKGROUND: Clozapine remains the antipsychotic of choice for refractory schizophrenia. Given the particular side effects of clozapine including neutropenia and myelosuppression, safety and efficacy of add-on chemotherapy for patients who are already under clozapine treatment remain unknown.OBJECTIVE: We present...

Cite
Usta NG, Poyraz CA, Aktan M, et al. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014;4(6):276-81doi: 10.1177/2045125314553610.
Usta, N. G., Poyraz, C. A., Aktan, M., & Duran, A. (2014). Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Therapeutic advances in psychopharmacology, 4(6), 276-81. https://doi.org/10.1177/2045125314553610
Usta, Nazife Gamze, et al. "Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma." Therapeutic advances in psychopharmacology vol. 4,6 (2014): 276-81. doi: https://doi.org/10.1177/2045125314553610
Usta NG, Poyraz CA, Aktan M, Duran A. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014 Dec;4(6):276-81. doi: 10.1177/2045125314553610. PMID: 25489479; PMCID: PMC4257985.
Copy Download .nbib Format: NLM
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.

Therapeutic advances in hematology

Owen CJ, Stewart DA.
PMID: 26288711
Ther Adv Hematol. 2015 Aug;6(4):161-70. doi: 10.1177/2040620715586528.

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder in the Western world and predominantly affects older people. Until recently, most studies in CLL focused on younger patients in whom intensive therapy with the addition of rituximab to...

Cite
Owen CJ, Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol. 2015;6(4):161-70doi: 10.1177/2040620715586528.
Owen, C. J., & Stewart, D. A. (2015). Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Therapeutic advances in hematology, 6(4), 161-70. https://doi.org/10.1177/2040620715586528
Owen, Carolyn J, and Stewart, Douglas A. "Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective." Therapeutic advances in hematology vol. 6,4 (2015): 161-70. doi: https://doi.org/10.1177/2040620715586528
Owen CJ, Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol. 2015 Aug;6(4):161-70. doi: 10.1177/2040620715586528. PMID: 26288711; PMCID: PMC4530370.
Copy Download .nbib Format: NLM
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.

Experimental and therapeutic medicine

Yang H, Du X, Xi Y.
PMID: 27446274
Exp Ther Med. 2016 Aug;12(2):771-776. doi: 10.3892/etm.2016.3401. Epub 2016 May 26.

The present study aimed to investigate the effects of survivin, an apoptosis inhibitor protein, on the efficacy of the fludarabine, vincristine, epirubicin, dexamethasone and thalidomide (FVADT) chemotherapy regime for the treatment of refractory multiple myeloma (MM). A total of...

Cite
Yang H, Du X, Xi Y. Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med. 2016;12(2):771-776doi: 10.3892/etm.2016.3401.
Yang, H., Du, X., & Xi, Y. (2016). Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Experimental and therapeutic medicine, 12(2), 771-776. https://doi.org/10.3892/etm.2016.3401
Yang, Hua, et al. "Effects of survivin on FVADT chemotherapy for refractory multiple myeloma." Experimental and therapeutic medicine vol. 12,2 (2016): 771-776. doi: https://doi.org/10.3892/etm.2016.3401
Yang H, Du X, Xi Y. Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med. 2016 Aug;12(2):771-776. doi: 10.3892/etm.2016.3401. Epub 2016 May 26. PMID: 27446274; PMCID: PMC4950835.
Copy Download .nbib Format: NLM
Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies.

Bone marrow research

Paiano S, Roosnek E, Tirefort Y, Nagy-Hulliger M, Masouridi S, Levrat E, Bernimoulin M, Huguet S, Casini A, Matthes T, Samii K, Passweg JR, Chalandon Y.
PMID: 25874131
Bone Marrow Res. 2015;2015:980924. doi: 10.1155/2015/980924. Epub 2015 Mar 22.

Different rabbit polyclonal antilymphocyte globulins (ATGs) are used in allogeneic hematopoietic stem cell transplantation (alloHSCT) to prevent graft-versus-host disease (GvHD). We compared 2 different ATGs in alloHSCT after reduced intensity conditioning (RIC) for hematological malignancies. We reviewed 30 alloHSCT...

Cite
Paiano S, Roosnek E, Tirefort Y, et al. Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. Bone Marrow Res. 2015;2015:980924doi: 10.1155/2015/980924.
Paiano, S., Roosnek, E., Tirefort, Y., Nagy-Hulliger, M., Masouridi, S., Levrat, E., Bernimoulin, M., Huguet, S., Casini, A., Matthes, T., Samii, K., Passweg, J. R., & Chalandon, Y. (2015). Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. Bone marrow research, 2015980924. https://doi.org/10.1155/2015/980924
Paiano, Sandra, et al. "Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies." Bone marrow research vol. 2015 (2015): 980924. doi: https://doi.org/10.1155/2015/980924
Paiano S, Roosnek E, Tirefort Y, Nagy-Hulliger M, Masouridi S, Levrat E, Bernimoulin M, Huguet S, Casini A, Matthes T, Samii K, Passweg JR, Chalandon Y. Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. Bone Marrow Res. 2015;2015:980924. doi: 10.1155/2015/980924. Epub 2015 Mar 22. PMID: 25874131; PMCID: PMC4385613.
Copy Download .nbib Format: NLM
Small Bowel Lymphoma.

Current treatment options in gastroenterology

Rawls RA, Vega KJ, Trotman BW.
PMID: 12521569
Curr Treat Options Gastroenterol. 2003 Feb;6(1):27-34. doi: 10.1007/s11938-003-0030-9.

Treatment of small bowel lymphoma requires the expertise of medical and surgical subspecialists. The two most important factors that determine the optimal treatment are histology and staging of small bowel lymphoma. Other factors that may affect treatment include age,...

Cite
Rawls RA, Vega KJ, Trotman BW. Small Bowel Lymphoma. Curr Treat Options Gastroenterol. 2003;6(1):27-34doi: 10.1007/s11938-003-0030-9.
Rawls, R. A., Vega, K. J., & Trotman, B. W. (2003). Small Bowel Lymphoma. Current treatment options in gastroenterology, 6(1), 27-34. https://doi.org/10.1007/s11938-003-0030-9
Rawls, Renard A., et al. "Small Bowel Lymphoma." Current treatment options in gastroenterology vol. 6,1 (2003): 27-34. doi: https://doi.org/10.1007/s11938-003-0030-9
Rawls RA, Vega KJ, Trotman BW. Small Bowel Lymphoma. Curr Treat Options Gastroenterol. 2003 Feb;6(1):27-34. doi: 10.1007/s11938-003-0030-9. PMID: 12521569.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 475 entries